Gastrointestinal Cancer News

BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.

Patients with high-risk T1 rectal cancer were at greater risk for recurrence after surgical resection than those with colon cancer, although no significant differences were reported after endoscopic local resection, according to research.

For individuals diagnosed with cancer, guideline-concordant exercise reduced all-cause mortality by 25% compared with patients with cancer who did not exercise, study results published in Journal of Clinical Oncology showed.

Higher BMI increased the risk for obesity-related cancer among a cohort of European adults, irrespective of cardiometabolic disease status, according to study results.

The combination of a sensitizing drug and stereotactic body radiation therapy improved treatment outcomes among patients with locally advanced pancreatic cancer, according to study results published in The Lancet Oncology.

To address ongoing chemotherapy drug shortages, ASCO convened a multidisciplinary panel of oncologists, ethicists and patient advocates to expedite clinical guidance for navigating care where rationing or alternative therapies are needed.

A phase 1/phase 2 study will evaluate the efficacy and safety of azeliragon for patients refractory to first-line treatment for metastatic pancreatic cancer.

Precision oncology therapies requiring biomarker testing comprised 43% of all FDA oncology drug approvals between 1998 and 2022, study results published in Cancer Discovery showed.

November marks Stomach Cancer Awareness Month, a time to raise awareness about risk factors, prevention and early detection of stomach cancer, which is expected to result in more than 11,000 deaths in 2023.

The FDA announced several regulatory actions.